Excited to announce the launch of Myris Therapeutics, developing ultra-high DAR ADCs for cancer. Congratulations to Laura E. Benjamin and her talented team! Proud to be a member of the Myris board as we work to build this powerful new company.
Today we are sharing with the world the fruits of our year of growing and rebranding. Myris Therapeutics has had a successful year with new leaders, new strategies and new programs. I am so proud of our talented group of scientists and what we have accomplished. We have shown that we can build Antibody-Drug-Conjugates with 50-300 payloads, either single payloads or mixed, that they work both in cells and animals and that they do indeed improve the therapeutic index. We have made molecules that are both more potent and safer than the small molecules when delivered systemically. Please stay tuned and follow our continuing journey to bring important medicines to cancer patients. https://lnkd.in/dgapynYH
Pioneering CEO driving cancer immunotherapy breakthroughs with innovative antibodies.
1mo👍👍👍